Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10338045rdf:typepubmed:Citationlld:pubmed
pubmed-article:10338045lifeskim:mentionsumls-concept:C0018957lld:lifeskim
pubmed-article:10338045lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:10338045lifeskim:mentionsumls-concept:C0242602lld:lifeskim
pubmed-article:10338045lifeskim:mentionsumls-concept:C0439234lld:lifeskim
pubmed-article:10338045lifeskim:mentionsumls-concept:C1883709lld:lifeskim
pubmed-article:10338045pubmed:issue9lld:pubmed
pubmed-article:10338045pubmed:dateCreated1999-7-6lld:pubmed
pubmed-article:10338045pubmed:abstractTextIn the present study we have used cell culture assays in order to assess the damage in the haematopoietic system 1 year after peripheral blood stem cell transplantation (PBSCT), and to establish at what level, haematopoietic progenitor cells (HPC) or stroma, this damage occurs. Thirty-one patients, nine breast cancer (BC), 17 non-Hodgkin lymphoma (NHL) and five Hodgkin disease (HD), who had received autologous PBSCT were included. Forty-eight normal subjects who had given informed consent were used as controls. Results were also compared with a matched group of patients (25 cases) prior to PBSCT. Progenitor cells were analysed using CFU-GM and plastic adherent delta (Pdelta) assays. Long-term bone marrow cultures (LTBMC) in one and two stages were established. One year after transplant both the number of committed progenitor cells and the CFU-GM production in LTBMC were significantly reduced in the three groups of patients when compared with controls (P < 0.05 or P < 0.01). Two-stage LTBMC experiments showed that the impairment in CFU-GM production was due to damage in both patients' stroma and haematopoietic progenitor cells (HPC). All patients, except those with HD, showed a decreased stromal layer confluence (P < 0.05), with significant differences in cell composition as compared to normal bone marrow (P = 0.001). When all these variables were compared with pretransplant results, we observed that stroma formation was significantly lower after PBSCT (P < 0.05), while the number of progenitor cells analysed by the Pdelta assay was significantly increased (P < 0.05). We can conclude that even 1 year after PBSCT, both the committed HPC and BM stroma remain damaged.lld:pubmed
pubmed-article:10338045pubmed:languageenglld:pubmed
pubmed-article:10338045pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10338045pubmed:citationSubsetIMlld:pubmed
pubmed-article:10338045pubmed:statusMEDLINElld:pubmed
pubmed-article:10338045pubmed:monthMaylld:pubmed
pubmed-article:10338045pubmed:issn0268-3369lld:pubmed
pubmed-article:10338045pubmed:authorpubmed-author:FernandezEElld:pubmed
pubmed-article:10338045pubmed:authorpubmed-author:del CañizoCClld:pubmed
pubmed-article:10338045pubmed:authorpubmed-author:GutierrezNNlld:pubmed
pubmed-article:10338045pubmed:authorpubmed-author:LopezNNlld:pubmed
pubmed-article:10338045pubmed:authorpubmed-author:MateosVVlld:pubmed
pubmed-article:10338045pubmed:authorpubmed-author:VazquezLLlld:pubmed
pubmed-article:10338045pubmed:authorpubmed-author:CaballeroDDlld:pubmed
pubmed-article:10338045pubmed:authorpubmed-author:San MiguelJ...lld:pubmed
pubmed-article:10338045pubmed:authorpubmed-author:BrufauAAlld:pubmed
pubmed-article:10338045pubmed:issnTypePrintlld:pubmed
pubmed-article:10338045pubmed:volume23lld:pubmed
pubmed-article:10338045pubmed:ownerNLMlld:pubmed
pubmed-article:10338045pubmed:authorsCompleteYlld:pubmed
pubmed-article:10338045pubmed:pagination901-5lld:pubmed
pubmed-article:10338045pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:meshHeadingpubmed-meshheading:10338045...lld:pubmed
pubmed-article:10338045pubmed:year1999lld:pubmed
pubmed-article:10338045pubmed:articleTitleHaematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation.lld:pubmed
pubmed-article:10338045pubmed:affiliationServicio y Cátedra de Hematología, Hospital Universitario y Universidad de Salamanca, Spain.lld:pubmed
pubmed-article:10338045pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10338045pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed